Cited by 38Malaria Research and ControlGlobal Maternal and Child HealthHIV/AIDS Research and Interventions

Intermittent preventive treatment of malaria in pregnancy: at the crossroads of public health policy

Chico, R. Matthew, Chandramohan, Daniel·2011·Tropical Medicine & International Health

Abstract

Summary: The intermittent preventive treatment of malaria in pregnancy (IPTp) with sulphadoxine‐pyrimethamine (SP) has been a key component of the focused antenatal care package for nearly a decade, reducing the burden of low birthweight attributable to malaria in sub‐Saharan Africa. However, SP has lost parasite sensitivity in many sub‐Saharan locations during the same period, rendering its beneficial effect in IPTp debatable. Malaria transmission has also declined in some epidemiological settings. There is no evidence to suggest, however, that the risk of malaria in pregnancy without preventive measures has declined in the same locations. Thus, the urgency to identify efficacious drugs and/or new strategies to prevent malaria in pregnancy remains as great as ever. We summarise the results of recently published SP‐IPTp studies from areas of high drug resistance and/or low malaria transmission. We also present the evidence for mefloquine and azithromycin‐based combinations (ABCs), two leading drug options to replace SP in IPTp. We discuss optimal dosing for ABCs and their likely protection against several sexually transmitted and reproductive tract infections. We also summarise data from a diagnosis‐based alternative to IPTp known as the intermittent screening and treatment (IST) for malaria. Clinical and operational research is urgently needed to compare birth outcomes achieved by IPTp with ABCs vs. IST using an efficacious antimalarial therapy.

Integrity signals

Registry

Crossref · 10.1111/j.1365-3156.2011.02765.x

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Increasing resistance to mefloquine further restricts treatment options.

    “However, the availability of quinine is limited, and increasing resistance to mefloquine further restricts these options [195].”

    From Current update on malaria in pregnancy: a systematic review (2025) · cites this paper as [195]

  • The availability of quinine is limited.

    “However, the availability of quinine is limited, and increasing resistance to mefloquine further restricts these options [195].”

    From Current update on malaria in pregnancy: a systematic review (2025) · cites this paper as [195]

  • Malaria treatment options for pregnant women with uncomplicated, chloroquine-resistant P. falciparum or P. vivax infections are limited to mefloquine or quinine plus clindamycin.

    “Malaria treatment options for pregnant women with uncomplicated, chloroquine-resistant P.falciparum or P.vivax infections are limited to mefloquine or quinine plus clindamycin.”

    From Current update on malaria in pregnancy: a systematic review (2025) · cites this paper as [195]

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Chico, R. M., & Chandramohan, D.
Affiliations
London School of Hygiene & Tropical Medicine (GB)
Corresponding author
Chico, R. Matthew
Venue
Tropical Medicine & International Health
Publisher
Wiley
Published
2011-04-07
Volume
16
Issue
7
Pages
774-785
ISSN
  • 1360-2276 (ISSN-L)
  • 1365-3156
OpenAlex
W1573701953
Cited by
38
References
89
Citations by year
2026: 1 · 2025: 1 · 2023: 2 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 2 · 2016: 1 · 2015: 3 · 2014: 2 · 2013: 5 · 2012: 8
FWCI
0.87
Type
journal article
Language
en
Open access
closed
Locations
  • Tropical Medicine & International Health (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Global Maternal and Child Health
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Keywords
intermittent preventive treatment in pregnancy, sulfadoxine-pyrimethamine, mefloquine, intermittent screening and treatment, antimalarial drug resistance, malaria in pregnancy, low birth weight, focused antenatal care, sexually transmitted infections, reproductive tract infections, malaria transmission, sub-Saharan Africa, public health policy
MeSH terms
Adult, Antimalarials, Clinical Trials as Topic, Drug Administration Schedule, Drug Combinations, Drug Resistance, Drug Therapy, Combination, Female, Humans, Malaria, Pregnancy, Prenatal Care, Public Health, Pyrimethamine, Sexually Transmitted Diseases, Sulfadoxine, Pregnancy Complications, Parasitic, Mefloquine, Treatment Outcome, AIDS-Related Opportunistic Infections, Africa South of the Sahara, Azithromycin, Anti-HIV Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review